The Relationship between Hematopoietic Scoring System Composed of HB，PLT and MCV and Prognosis and Curative Effect of Multiple Myeloma Patients.
10.19746/j.cnki.issn.1009-2137.2022.02.026
- Author:
Li-Min SONG
1
;
Yan-Ping MA
2
;
Ru XUE
1
;
Lu CHENG
1
Author Information
1. Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China,E-mail:myanp18@163.com.
- Publication Type:Journal Article
- Keywords:
bortezomib;
curative effect;
hematopoietic score;
multiple myeloma;
prognosis
- MeSH:
Bortezomib/therapeutic use*;
Erythrocyte Indices;
Hemoglobins/therapeutic use*;
Humans;
Multiple Myeloma/diagnosis*;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(2):481-486
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the prognostic value of hemopoietic scoring system composed of hemoglobin (HB), platelet count (PLT) and mean corpuscular volume (MCV) in MM patients and its correlation with curative effect.
METHODS:The clinical data of 172 newly diagnosed MM patients treated by bortezomib as the first-line regimen in our hospital from May 2014 to December 2019 were collected, three variables (HB≤100 g/L, PLT≤150×109/L, MCV≥96 fl) were introduced, each variable was distributed 1 score, the patients were divided into four groups (0, 1, 2 and 3 points in group 1, 2, 3 and 4, respectively), and the clinical characteristics and prognosis of the patients in the four groups were analyzed. The initial efficacy evaluation after 3-4 courses of treatment was carried out, and the curative effect of the patients in the different hematopoiesis score groups were compared.
RESULTS:The median OS time of the patients in group 1, 2, 3 and 4 was 27.0, 22.5, 20.7 and 18.1 months, while the median PFS time were 23.0, 19.0, 18.0 and 14.0 months, respectively. The OS and PFS of the patients in low score group were significantly better than those in high score group (P=0.045, P=0.048). There was no significant difference in the curative effect of the patients treated by bortezomib after 3-4 courses (P>0.05).
CONCLUSION:Hematopoiesis score can preliminarily predict the overall survival of newly diagnosed MM patients, but there is no significant difference between different scoring groups in the initial curative effect.
